

Task Force on Repurposing of Drugs (TFORD) for COVID-19

Patent status in India: by GNANLEX

Ribavirin

A. Active patents

S.no.	Title	Assignee	Patent details	Type of patent	Remarks
1.	Composition Of An Anti-Viral Compound	Aurobindo Pharma Limited	App no/Grant no: IN279483 (906/CHE/2005) Filing date: 08/07/2005 Grant date: 24/01/2017 Expected expiry date: 08/07/2025 Form 27: patented invention (tablet and capsules) is being worked in India	Ribavirin oral pharmaceutical composition in tablet and capsules forms	Patent Barrier. However, can be worked around.

B. Pending applications - None

C. Expired/Lapsed applications

S.no.	Title	Assignee	Patent/Application details	Type of patent	Remarks
1.	Process of preparing 1,2,4-triazole nucleosides	ICN pharmaceuticals inc.,	Grant No: IN142290 App No: 1026/CAL/1974 Filing Date: 09/05/1974 Status: Patent Has Expired	Ribavirin API and Process	No Patent Barrier
2.	An orally administrable solid dosage form comprising a ribavirin compacted composition and a method of producing the same	Schering Corporation	Grant No: IN216233 Filing Date: 21/06/2000 Status: Patent Has Ceased On 21/12/2011	Ribavirin tablet dosage form	No Patent Barrier
3.	A stable liquid formulation comprising ribavirin	Schering Corporation And Merck Sharp & Dohme Corp	Grant No: IN213086 App No: 897/CHENP/2004 Filing Date: 28/04/2004 Status: Patent Has Ceased On 31/10/2014	Ribavirin oral liquid dosage form	No Patent Barrier
4.	Process for the preparation of ribavirin	Clariant Life Science Molecules (Italia) S.P.A.	Grant No: IN228965 App No: 166/CHENP/2004 Filing Date: 28/01/2004 Status: Patent Has Ceased On 30/07/2018	Ribavirin Process	No Patent Barrier
5.	A process for the preparation of l-ribavirin	Clariant Life Science Molecules (Italia) S.P.A	Grant No: IN227462 App No: 177/CHENP/2004	L-Ribavirin Process	No Patent Barrier

Commissioned by



Task Force on Repurposing of Drugs (TFORD) for COVID-19

Patent status in India: by GNANLEX

			Filing Date: 29/01/2004 Status: Patent Has Ceased On 26/07/2010		
6.	An improved process for the preparation of an antiviral agent	Aurobindo Pharma Limited	Grant No: IN238921 App No: 383/CHE/2004 Filing Date: 27/04/2004 Status: Patent Has Ceased On 28/04/2014	Ribavirin Process from intermediate b-D-ribofuranose	No Patent Barrier
7.	Modulation of immune response by ribavirin	ICN Pharmaceuticals, INC.	Grant No: - App No: IN/PCT/2001/00616/DEL Filing Date: - Status: Application Does Not Exist Or Not Yet Published	Modulation Of Immune Response By Ribavirin	No Patent Barrier
8.	Process for preparing quick dissolving, high loading ribavirin compositions	Geneva Pharmaceuticals, Inc.	Grant No: - App No: 924/CHENP/2004 Filing Date: 30/04/2004 Status: Current Status Is Not Available Online. However, Application Seems To Have Been Abandoned.	Ribavirin quick dissolving formulation and process thereof.	No Patent Barrier
9.	Prodrugs of ribavirin with improved hepatic delivery	New River Pharmaceuticals Inc.	Grant No: - App No: 1810/KOLNP/2007 Filing Date: 21/05/2007 Status: Current Status Is Not Available Online. However, Application Seems To Have Been Abandoned.	Prodrugs Of Ribavirin	No Patent Barrier
10.	Pharmaceutical composition comprising ribavirin and process for making them	Jubilant Life Sciences Limited	Grant No: - App No: 565/DEL/2014 Filing Date: 28/02/2014 Status: Current Status Is Not Available Online.	Ribavirin solid oral dosage form	No Patent Barrier
11.	Pharmaceutical compositions of ribavirin	Glaxosmithkline Intellectual Property limited and Liquidia Technologies Inc.	App No: 201817015437 Filing Date: 24/04/2018 Status: Current Status Is Not Available Online.	Ribavirin inhalable antiviral pharmaceutical compositions	No Patent Barrier

Disclaimer:

Search results are up to 11th April 2020

GNANLex's Opinion / Report as hereinabove is to the best of our knowledge, true and accurate as of the date compiled based on available information. However, no guarantee is made as to its accuracy, reliability or completeness. The final user is expected to assume sole liability for any patent infringement that occurs by following our recommendations or using the information given. Before using, user should determine the suitability of the information for his intended use. The risk and liability, if any, in connection therewith, is solely that of the user.

Commissioned by

